MN-DPDP - ENHANCED MR-IMAGING OF MALIGNANT LIVER-LESIONS - EFFICACY AND SAFETY IN 20 PATIENTS

被引：28

作者：

AICHER, KP ^{[1
]}

LANIADO, M ^{[1
]}

KOPP, AF ^{[1
]}

GRONEWALLER, E ^{[1
]}

DUDA, SH ^{[1
]}

CLAUSSEN, CD ^{[1
]}

机构：

[1] EBERHARD KARLS UNIV TUBINGEN,DEPT DIAGNOST RADIOL,HOPPE SEYLER STR 3,W-7400 TUBINGEN,GERMANY

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 05期

关键词：

CONTRAST ENHANCEMENT; CONTRAST MEDIA; EFFECTS; TOXICITY; LIVER NEOPLASMS; MR; MANGANESE;

D O I：

10.1002/jmri.1880030507

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];

摘要：

Twenty patients with malignant liver lesions underwent magnetic resonance (MR) imaging with manganese (II) DPDP [N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate)] to evaluate the safety and efficacy of the contrast agent. In two groups of 10 patients each, 5 mumol/kg Mn-DPDP was administered intravenously (3 mL/min) at a concentration of either 50 or 10 mumol/mL. T1- and T2-weighted images were obtained with a 1.5-T imager. Six patients reported a total of eight instances of side effects (flush, feeling of warmth, metallic taste) of which seven occured at the 50 mumol/mL concentration. A significant decrease in alkaline phosphatase levels 2 hours after injection was recorded. On T1-weighted images, the 10 mumol/mL formulation yielded significantly greater increases in contrast-to-noise ratio (79.8%-137.5%) than the 50 mumol/mL formulation (46.2%-86.6%). In a blinded reader study of 10 patients with one to five lesions each, no lesion was missed on Mn-DPDP-enhanced T1-weighted images; however, four false-positive foci were identified. The authors conclude that slow administration of 5 mumol/kg Mn-DPDP at a concentration of 10 mumol/mL is safe and efficient enough to proceed to further clinical trials.

引用

页码：731 / 737

页数：7

共 19 条

[1]

Ferrucci JT, Liver tumor imaging: current concepts, AJR, 155, pp. 473-484, (1990)

[2]

Mirowitz SA, Lee JKT, Gutierrez E, Brown JJ, Heiken JP, Eilenberg SS, Dynamic gadolinium‐enhanced rapid acquisition spin‐echo MR imaging of the liver, Radiology, 179, pp. 371-376, (1991)

[3]

Stark DD, Weissleder R, Elizondo G, Et al., Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver, Radiology, 168, pp. 297-301, (1988)

[4]

Elizondo G, Fretz CJ, Stark DD, Et al., Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging, Radiology, 178, pp. 73-78, (1991)

[5]

Lim KO, Stark DD, Leese PT, Pfefferbaum A, Rocklage SM, Quay SC, Hepatobiliary MR imaging: first human experience with MnDPDP, Radiology, 178, pp. 79-82, (1991)

[6]

Rummeny E, Ehrenheim C, Gehl HB, Et al., Manganese‐DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors: results of clinical phase II trials in Germany including 141 patients, Invest Radiol, 26, (1991)

[7]

Bernardino ME, Young SW, Lee JK, Weinreb JC, Hepatic MR imaging with Mn‐DPDP: safety, image quality, and sensitivity, Radiology, 183, pp. 53-58, (1992)

[8]

Laniado M, Ehrenheim C, Gehl HB, Hamm B, Rummeny E, Steudel A, MnDPDP: safety profile after phase II clinical trials in 140 patients (abstr), Radiology, 179, P, (1991)

[9]

Hamm B, Vogl TJ, Branding G, Et al., Focal liver lesions: MR imaging with Mn‐DPDP: initial clinical results in 40 patients, Radiology, 182, pp. 167-174, (1992)

[10]

Rocklage SM, Cacheris WP, Quay SC, Hahn FE, Raymond KN, Manganese(II)N.N'‐dipyridoxylethylenediamine‐N, N'‐diacetate 5,5′bis(phosphate): synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement, Inorg Chem, 28, pp. 477-485, (1989)

← 1 2 →